We are pioneers in targeting C1q, the initiating molecule of the classical complement pathway. By stopping the start of this pathway, our C1q inhibitors are designed to treat multiple complement-mediated diseases of the body, eye, and brain.Our Platform
Our Path. Many Opportunities.
Our platform technology uses an upstream approach to target the classical complement cascade, inhibiting C1q as the initiator of distinct disease processes. Aberrant activation of C1q leads to tissue damage in antibody-mediated autoimmune diseases and complement-mediated neurodegenerative diseases.
We are leading the development of novel inhibitors that are designed to block C1q and the entire classical complement pathway. We are developing these therapeutics for autoimmune and neurodegenerative diseases of the body, eye, and brain.Our Pipeline